Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

284
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
284
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Primary Human Papillomavirus Testing Vs Cotesting: Clinical Outcomes In Populations With Different Disease Prevalence.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Primary Human Papillomavirus Testing Vs Cotesting: Clinical Outcomes In Populations With Different Disease Prevalence.

Related Experiment Video

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K

Primary human papillomavirus testing vs cotesting: clinical outcomes in populations with different disease prevalence.

Shrutikona Das1, Nicolas Wentzensen1, George F Sawaya2

  • 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

Journal of the National Cancer Institute
|June 3, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Primary human papillomavirus (HPV) testing is effective and requires fewer procedures than cotesting. Cotesting offers minimal additional benefit in detecting cervical precancer or cancer, suggesting primary HPV testing is a better strategy.

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.4K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K

Related Experiment Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.4K
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

10.4K

Area of Science:

  • Gynecology
  • Oncology
  • Public Health

Background:

  • Primary human papillomavirus (HPV) testing adoption in the US lags due to concerns about reduced sensitivity compared to HPV and cytology cotesting.
  • Understanding the trade-offs between primary HPV testing and cotesting is crucial for optimizing cervical cancer screening protocols.

Purpose of the Study:

  • To compare the benefits and harms of primary HPV testing versus HPV and cytology cotesting across diverse US populations.
  • To quantify the additional detection of cervical intraepithelial neoplasia grade 3 or cancer with cotesting compared to primary HPV testing.

Main Methods:

  • Utilized data from the National Breast and Cervical Cancer Early Detection Program and Kaiser Permanente of Northern California.
  • Analyzed screening outcomes in four US populations with varying cervical precancer and cancer prevalence.
  • Compared the number of laboratory tests and colposcopies required for each screening strategy.

    • Main Results:

    • Cotesting consistently required more laboratory tests and colposcopies than primary HPV testing across all settings.
    • The incremental detection of cervical intraepithelial neoplasia grade 3 or cancer by cotesting decreased as population prevalence declined.
    • In high-prevalence groups, cotesting detected 71 additional cases per 100,000, while in low-prevalence groups, it detected only 4 additional cases per 100,000.

    Conclusions:

    • Primary HPV testing demonstrates a more favorable benefit-to-harm ratio compared to cotesting.
    • The marginal benefit of cotesting diminishes significantly in lower-prevalence screening populations.
    • These findings support the wider implementation of primary HPV testing for cervical cancer screening.